TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease ...
The nonprofit provider of services for adults with developmental disabilities has named its next leader as its longtime CEO retires.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results